Plasma Derived Therapies Market Size is valued at USD 21.9 Bn in 2024 and is predicted to reach USD 42.6 Bn by the year 2034 at a 7.0% CAGR during the forecast period for 2025-2034.
Immune deficiencies, bleeding problems, and genetic diseases are only some conditions that must be treated using plasma-derived therapies. Plasma fractionation, which involves separating and purifying the plasma to remove particular proteins or antibodies, is the method used to produce plasma-derived medicines. High frequency of chronic blood illnesses, improvements in plasma collection & fractionation technology, and increased need for safe, efficient, and minimally invasive treatment techniques are projected to boost the market for plasma-derived therapeutics.
The global ageing population, as well as the increased frequency of chronic diseases, are significant factors driving this market. Immune deficiencies, haemophilia, and liver illnesses are among the many diseases that can be treated with plasma-derived therapies such as immunoglobulins, clotting factors, and albumin. The expanding patient population and the need for efficient therapeutic choices drive the need for plasma-derived therapeutics.
Improvements in plasma fractionation methods and technology facilitate market expansion. Advances in plasma collection, processing, and purification techniques have resulted from ongoing research and development in the biotechnology and healthcare fields. These developments raise the effectiveness and security of plasma-derived medicines, further promoting their market adoption.
The rising incidence of chronic illnesses and rare disorders among people has emerged as a crucial growth element that has assisted the market in achieving a considerable position. In order to offer cutting-edge healthcare facilities that will significantly benefit society, both the government and private organisations have launched numerous measures. People have been encouraged to use these advanced treatment options in order to get the best results, thanks to multiple government efforts that provide reimbursement options through insurance companies.
The Plasma Derived Therapies market is segmented on the basis of product type and application type. The market is segmented as Immunoglobulin, Coagulation factors, Albumin, and Others based on product type. The market is segmented by application type into Haemophilia, Primary Immunodeficiency Disease, Idiopathic Thrombocytopenic Purpura, and others.
The immunoglobulin segment is anticipated to rule the market during the projected period. Numerous immunological deficiencies and autoimmune diseases are commonly treated using immunoglobulins. The demand for immunoglobulin therapy is driven by the rising prevalence of these diseases as well as rising awareness and diagnosis. Improvements in immunoglobulin production and purification due to advances in plasma fractionation techniques have raised the bar for both quality and safety. Additionally, improved access to immunoglobulin therapy has increased access to healthcare facilities, particularly in emerging economies, further strengthening their market domination.
The haemophilia segment is projected to grow at a rapid rate in the global Plasma Derived Therapies market as it is a persistent bleeding disorder that needs to be regularly treated with plasma-derived clotting factors. The rising prevalence of haemophilia and improvements in available treatments drives the demand for plasma-derived therapeutics in this market. Second, the care of haemophilia has been greatly improved, improving patient outcomes, with the availability of recombinant clotting factors and extended half-life medicines. Additionally, the dominance of the haemophilia segment in the market for plasma-derived therapeutics is attributed to the increasing awareness and diagnosis of haemophilia, as well as supportive government initiatives and the development of the healthcare infrastructure.
The projection period is expected to see North America dominate the global market, which was valued at USD 16.10 billion in 2022. Several variables are responsible for this region's largest market share. Major corporations that create and sell technologically cutting-edge plasma-derived therapies and goods are some of the variables that favourably influence the region's development. Additionally, the U.S. having the greatest concentration of plasma fractionation facilities greatly impacts the market's expansion. The second-largest market share belonged to Europe, on the other hand. This is because immunodeficiency and bleeding disorders are becoming more common in the area, and increased investments in these systems are accelerating market growth in the area.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 21.9 Bn |
|
Revenue Forecast In 2034 |
USD 42.6 Bn |
|
Growth Rate CAGR |
CAGR of 7.0% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million, and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, By Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; South Korea; Southeast Asia |
|
Competitive Landscape |
CSL Behring, Takeda Pharmaceutical Company Limited, BPL, ADMA Biologics, Biotest AG, Octapharma, Grifols, Kamada Pharmaceuticals, SK Plasma, Kedrion, and Pfizer Inc. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Plasma Derived Therapies Market Snapshot
Chapter 4. Global Plasma Derived Therapies Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
Chapter 5. Market Segmentation 1: By Product Type Estimates & Trend Analysis
5.1. By Product Type & Market Share, 2024-2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Product Type:
5.2.1. Immunoglobulin,
5.2.2. Coagulation Factors,
5.2.3. Albumin,
5.2.4. Others
Chapter 6. Market Segmentation 2: By Application Type Estimates & Trend Analysis
6.1. By Product Type & Market Share, 2024-2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application Type:
6.2.1. Hemophilia
6.2.2. Primary Immunodeficiency Disease
6.2.3. Idiopathic Thrombocytopenic Purpura,
6.2.4. Others
Chapter 7. Plasma Derived Therapies Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Plasma Derived Therapies Market revenue (US$ Million) estimates and forecasts By Product Type, 2021-2034
7.1.2. North America Plasma Derived Therapies Market revenue (US$ Million) estimates and forecasts By Application Type, 2021-2034
7.1.3. North America Plasma Derived Therapies Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Plasma Derived Therapies Market revenue (US$ Million) by By Product Type, 2021-2034
7.2.2. Europe Plasma Derived Therapies Market revenue (US$ Million) estimates and forecasts By Application Type, 2021-2034
7.2.3. Europe Plasma Derived Therapies Market revenue (US$ Million) by country, 2021-2034
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. Pacific Plasma Derived Therapies UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Market revenue (US$ Million) by By Product Type, 2021-2034
7.3.2. Asia Pacific Plasma Derived Therapies Market revenue (US$ Million) estimates and forecasts By Application Type, 2021-2034
7.3.3. Asia Pacific Plasma Derived Therapies Market revenue (US$ Million) by country, 2021-2034
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America Plasma Derived Therapies Market revenue (US$ Million) by By Product Type, 2021-2034
7.4.2. Latin America Plasma Derived Therapies Market revenue (US$ Million) estimates and forecasts By Application Type, 2021-2034
7.4.3. Latin America Plasma Derived Therapies Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. Middle East & Africa
7.5.1. Middle East & Africa Plasma Derived Therapies Market revenue (US$ Million) by By Product Type, (US$ Million)
7.5.2. Middle East & Africa Plasma Derived Therapies Market revenue (US$ Million) estimates and forecasts By Application Type, 2021-2034
7.5.3. Middle East & Africa Plasma Derived Therapies Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.5.3.1. South Africa
7.5.3.2. GCC Countries
7.5.3.3. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. CSL Behring,
8.2.2. Takeda Pharmaceutical Company Limited,
8.2.3. BPL,
8.2.4. ADMA Biologics,
8.2.5. Biotest AG,
8.2.6. Octapharma,
8.2.7. Grifols,
8.2.8. Kamada Pharmaceuticals,
8.2.9. SK Plasma,
8.2.10. Kedrion
8.2.11. Pfizer Inc.
Plasma Derived Therapies Market By Product Type-
Plasma Derived Therapies Market By Application Type-
Plasma Derived Therapies Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
